How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness

Courtesy of: MindMed

The following post was written and/or published as a collaboration between ’s in-house sponsored content team and a financial partner of Benzinga.

Despite the fact that around 450 million people globally suffer from mental illnesses, access to mental healthcare is still a challenge in most parts of the world, including the U.S. As conversations about mental health grow more prominent, especially during the COVID-19 pandemic, there is a pressing need for new and innovative ways to provide treatment.

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED), known as MindMed, is on a mission to develop innovative, psychedelic-assisted treatments. Its drug pipeline includes trials related to psilocybin, LSD, MDMA, N,N-Dimethyltryptamine (DMT) and an ibogaine derivative, 18-Methoxycoronaridine (18-MC), to help treat mental health issues.

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The company brings together a team of experts with extensive biopharmaceutical experience to develop the next generation of psychedelic-inspired medicines and therapies.

MindMed to the Rescue

About 21 million Americans struggle with at least one form of substance use disorder. However, only 10% of the population currently receive treatment. Addiction is a chronic brain disease that stems from the neurology of the brain, driven by a set of disease processes including the dysregulation of dopamine, a potent neurotransmitter, in the brain’s reward/pleasure center.

MindMed is developing …

Full story available on Benzinga.com

More How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness